Permanent 100% Antimicrobial Medical Plastic

描述（由申请人提供）：永久性100%抗菌医用塑料对抗感染是整个医学界的主要目标之一，因为与感染患者护理相关的指数成本。技术创新，以减少交叉污染的病人留在医疗机构带来的感染，可以有重大影响的医疗界在美元和人的生命。大约5%至10%的患者在住院期间会接触某种形式的感染。据估计，医院每年花费超过300亿美元，超过10万人可能因医院感染而丧生。统计数据显示，主要包括用抗菌肥皂洗手的个人卫生并不经常发生，不足以防止医疗机构每年承受的300亿美元的支出。不幸的是，仅含有0.1-1.0%的可浸出抗微生物添加剂的医疗产品仅提供暂时的抗微生物作用，因为杀生物剂可以通过洗涤或擦拭医疗产品的表面而容易地去除。Brighton Development在NIH的支持下开发了一种100%永久性抗菌塑料，可用于医疗保健领域的许多医疗产品。在第二阶段，我们希望专注于利用这一发现作为永久性100%抗菌材料的可行性，并展示其在医疗环境中对抗感染的优势。Brighton Development将生成所需的数据，以获得EPA 100%抗菌产品的注册，并随后将这些产品提供给医疗保健界。该项目的目标与NIH消除HAI（卫生保健相关感染）的最高优先事项之一一致，该项目在资金和人类生命方面都具有巨大的影响。 公共卫生相关性：该提案旨在开发永久性的100%抗菌医用塑料产品，可用于减少医疗机构每年用于对抗患者感染的数十亿美元。统计数据显示，这一问题的严重程度影响了所有进入医院的人中的5-10%，即使有记录显示医院工作人员抗菌洗手的频率，医疗界每年的支出仍超过300亿美元。在NIH的支持下，在第一阶段开发的真正耐用的100%抗菌塑料材料可以在整个医疗机构的医疗产品中找到许多用途。作为第二阶段的一部分，100%抗菌产品将在EPA注册，随后提供给医疗保健界。该项目的目标与NIH消除HAI（卫生保健相关感染）的最高优先事项之一一致，该项目在资金和人类生命方面都具有巨大的影响。

DESCRIPTION (provided by applicant): PERMANENT 100% ANTIMICROBIAL MEDICAL PLASTIC Combating infections is one of the major goals of the entire medical community due to the exponential cost associated with care of an infected patient. Technology innovations to reduce infection brought about by cross-contamination of patients staying in healthcare facilities can have major impact to the medical community in terms of both dollars and human lives. Approximately 5% to 10% of all patients entering a hospital will contact some form of infection during their stay at the healthcare facility. It is estimated that hospitals spend over $30 billion annually and over 100,000 lives can be lost as a result of nosocomial infections. Statistics show that personal hygiene consisting mainly of hand washing with antimicrobial soaps does not occur frequently enough to prevent the $30 billion dollar expenditure that healthcare facilities endure on an annual basis. Unfortunately, medical products containing only 0.1-1.0% of leachable antimicrobial additives only provide temporary antimicrobial action because the biocidal agent can be easily removed by washing or wiping the surface of the medical product. Brighton Development has developed with NIH support a 100% permanent antimicrobial plastic that can be used in numerous medical products found in the healthcare community. In Phase II, we would like to focus on exploiting the feasibility of this discovery as a permanent 100% antimicrobial material and demonstrate its advantages in combating infection in the healthcare environment. Brighton Development will generate the required data to obtain registration of the 100% antimicrobial products with the EPA and subsequently provide these products to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives. PUBLIC HEALTH RELEVANCE: This proposal is aimed at developing permanent 100% antimicrobial medical plastic products that can be used to reduce the billions of dollars spent annually by healthcare facilities to combat patient infections. Statistics show that the magnitude of this problem affects from 5-10% of all people entering the hospital and accounts for annual expenditures by the medical community of over 30 billion dollars even with documented frequencies of antimicrobial hand washing by hospital staff. A truly durable 100% antimicrobial plastic material developed in Phase I with NIH support could find numerous uses in medical products throughout healthcare facilities. As a part of the Phase II, the 100% antimicrobial products will be registered with the EPA and subsequently provided to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives.